Tracked forImpact Factor
2.4CiteScore
42 daysTime to First Decision

Endocrines, Volume 5, Issue 4

December 2024 - 11 articles

Cover Story: Human pluripotent stem cells—whether derived from embryos (hESC) or adult tissues induced to pluripotency (hiPSC)—and adult multipotent mesenchymal stem cells (MSCs) might represent a possible solution to the restricted availability of insulin-producing cells for T1D cell therapy. However, ethical barriers prevent the wide use of hESC, hiPSC has not yet reached clinical feasibility, and MSCs still need to prove their clinical efficacy. A Vertex Inc. clinical trial for hESC in T1D immunosuppressed patients showed that four patients suspended insulin therapy after several months due to heavy financial burden. Proof of principle for stem cell use has been demonstrated, but time is required to expedite the process, eliminate immunosuppression, and cut back on expenses to validate stem cell types that are universally acceptable. View this paper

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (11)

Select all

Review

3 Citations

10,169 Views

13 Pages

Human Stem Cell Therapy for the Cure of Type 1 Diabetes Mellitus (T1D): A Hurdle Course between Lights and Shadows

Riccardo Calafiore,
Giovanni Luca,
Francesco Gaggia and
Giuseppe Basta

Endocrines2024, 5(4), 465-477;https://doi.org/10.3390/endocrines5040034

5 October 2024

Background: T1D is a severe metabolic disorder due to selective autoimmune pancreatic islet β-cell killing, which results in complete abrogation of endogenous insulin secretion. The affected patients, once the disease is clinically overt, must i...

Full Article

of 2

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Endocrines - ISSN 2673-396X

Imprint

Download Flyer